May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Purification of the Active Constitutent of Dispase for Vitreopharmacolysis
Author Affiliations & Notes
  • H.J. Kaplan
    Department of Ophthalmology & Visual Sciences, University of Louisville School of Medicine, Louisville, KY
  • T.H. Tezel
    Department of Ophthalmology & Visual Sciences, University of Louisville School of Medicine, Louisville, KY
  • L.V. Del Priore
    Department of Ophthalmology, Columbia University School of Medicine, New York, NY
  • Footnotes
    Commercial Relationships  H.J. Kaplan, Pavidon, LLC I, P; T.H. Tezel, Pavidon, LLC I, P; L.V. Del Priore, Pavidon, LLC I.
  • Footnotes
    Support  Pavidon, LLC
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5454. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.J. Kaplan, T.H. Tezel, L.V. Del Priore; Purification of the Active Constitutent of Dispase for Vitreopharmacolysis . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5454.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To identify and purify the active constituent(s) of Dispase responsible for enzymatic posterior vitreous detachment. Methods: The purity of Dispase I and II were analyzed by 2–D gel electrophoresis. Endotoxin contamination of both preparations was determined using the limulus lysate assay. Enzymatic autodegradation and activity of the constituents was tested with a colorimetric gelatinase assay. An active band was purified using a diffusion column. The ability of the purified protein to induce a posterior vitreous detachment was investigated in vitro using freshly enucleated porcine eyes. Results: Both Dispase I and II contains multiple impurities and are contaminated with endotoxin. The gelatinase activity of Dispase II was significantly lower than Dispase I because of higher amounts of non–protein impurities. The enzymatic activity of both preparations was mainly generated by a 38 kDa matrix metalloprotease that was purified in a gel column. The purified enzyme retained its activity on the gelatinase assay. Using freshly enucleated porcine eyes (n=10), the purified enzyme induced complete (8/10) and partial (2/10) PVD within 15 minutes; whereas 1/10 control eyes that received intravitreal BSS only revealed complete, 2/7 a partial PVD and 7/10 no PVD. The enzymatic activity of the purified protein was greater than crude Dispase I which induced fewer complete (3/10) and partial (6/10) PVDs. Conclusions: Crude Dispase contains endotoxin, which is known to cause intraocular inflammation within 24–48 hours of intravitreal injection in vivo. The active enzyme can be purified and has a higher enzymatic activity that crude Dispase I and II. Advances in the production of the purified protein have the potential to induce a safe enzymatic PVD in vivo.

Keywords: vitreoretinal surgery • vitreous • enzymes/enzyme inhibitors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×